PMC:7219429 / 2981-3439 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T16","span":{"begin":82,"end":90},"obj":"Disease"},{"id":"T17","span":{"begin":320,"end":329},"obj":"Disease"}],"attributes":[{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":" [2], a preliminary clinical trial was implemented in France on a small cohort of COVID-19 patients [3]. A significant viral load reduction was observed in the 20 patients treated with CLQ-OH [3], a CLQ derivative with increased solubility in water and decreased toxicity [4]. With the aim of preventing bacterial super-infection, six additional patients in this trial also received ATM for 5 days. All these patients had undetectable viral load after 6 days"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T33","span":{"begin":2,"end":7},"obj":"http://purl.obolibrary.org/obo/CLO_0001236"},{"id":"T34","span":{"begin":64,"end":65},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T35","span":{"begin":105,"end":106},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T36","span":{"begin":197,"end":198},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T37","span":{"begin":286,"end":289},"obj":"http://purl.obolibrary.org/obo/PR_000001343"}],"text":" [2], a preliminary clinical trial was implemented in France on a small cohort of COVID-19 patients [3]. A significant viral load reduction was observed in the 20 patients treated with CLQ-OH [3], a CLQ derivative with increased solubility in water and decreased toxicity [4]. With the aim of preventing bacterial super-infection, six additional patients in this trial also received ATM for 5 days. All these patients had undetectable viral load after 6 days"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T49","span":{"begin":243,"end":248},"obj":"Chemical"},{"id":"T50","span":{"begin":383,"end":386},"obj":"Chemical"}],"attributes":[{"id":"A49","pred":"chebi_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/CHEBI_15377"},{"id":"A50","pred":"chebi_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"}],"text":" [2], a preliminary clinical trial was implemented in France on a small cohort of COVID-19 patients [3]. A significant viral load reduction was observed in the 20 patients treated with CLQ-OH [3], a CLQ derivative with increased solubility in water and decreased toxicity [4]. With the aim of preventing bacterial super-infection, six additional patients in this trial also received ATM for 5 days. All these patients had undetectable viral load after 6 days"}

{"project":"LitCovid-sentences","denotations":[{"id":"T28","span":{"begin":105,"end":276},"obj":"Sentence"},{"id":"T29","span":{"begin":277,"end":398},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":" [2], a preliminary clinical trial was implemented in France on a small cohort of COVID-19 patients [3]. A significant viral load reduction was observed in the 20 patients treated with CLQ-OH [3], a CLQ derivative with increased solubility in water and decreased toxicity [4]. With the aim of preventing bacterial super-infection, six additional patients in this trial also received ATM for 5 days. All these patients had undetectable viral load after 6 days"}

{"project":"LitCovid-PubTator","denotations":[{"id":"114","span":{"begin":91,"end":99},"obj":"Species"},{"id":"115","span":{"begin":163,"end":171},"obj":"Species"},{"id":"116","span":{"begin":346,"end":354},"obj":"Species"},{"id":"117","span":{"begin":409,"end":417},"obj":"Species"},{"id":"125","span":{"begin":185,"end":191},"obj":"Chemical"},{"id":"126","span":{"begin":199,"end":202},"obj":"Chemical"},{"id":"127","span":{"begin":243,"end":248},"obj":"Chemical"},{"id":"132","span":{"begin":82,"end":90},"obj":"Disease"},{"id":"133","span":{"begin":253,"end":271},"obj":"Disease"},{"id":"134","span":{"begin":304,"end":329},"obj":"Disease"}],"attributes":[{"id":"A114","pred":"tao:has_database_id","subj":"114","obj":"Tax:9606"},{"id":"A115","pred":"tao:has_database_id","subj":"115","obj":"Tax:9606"},{"id":"A116","pred":"tao:has_database_id","subj":"116","obj":"Tax:9606"},{"id":"A117","pred":"tao:has_database_id","subj":"117","obj":"Tax:9606"},{"id":"A126","pred":"tao:has_database_id","subj":"126","obj":"MESH:D002738"},{"id":"A127","pred":"tao:has_database_id","subj":"127","obj":"MESH:D014867"},{"id":"A132","pred":"tao:has_database_id","subj":"132","obj":"MESH:C000657245"},{"id":"A133","pred":"tao:has_database_id","subj":"133","obj":"MESH:D066126"},{"id":"A134","pred":"tao:has_database_id","subj":"134","obj":"MESH:D001424"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" [2], a preliminary clinical trial was implemented in France on a small cohort of COVID-19 patients [3]. A significant viral load reduction was observed in the 20 patients treated with CLQ-OH [3], a CLQ derivative with increased solubility in water and decreased toxicity [4]. With the aim of preventing bacterial super-infection, six additional patients in this trial also received ATM for 5 days. All these patients had undetectable viral load after 6 days"}

{"project":"2_test","denotations":[{"id":"32405156-32074550-48150995","span":{"begin":2,"end":3},"obj":"32074550"},{"id":"32405156-32194981-48150996","span":{"begin":273,"end":274},"obj":"32194981"},{"id":"T20596","span":{"begin":2,"end":3},"obj":"32074550"},{"id":"T63350","span":{"begin":273,"end":274},"obj":"32194981"}],"text":" [2], a preliminary clinical trial was implemented in France on a small cohort of COVID-19 patients [3]. A significant viral load reduction was observed in the 20 patients treated with CLQ-OH [3], a CLQ derivative with increased solubility in water and decreased toxicity [4]. With the aim of preventing bacterial super-infection, six additional patients in this trial also received ATM for 5 days. All these patients had undetectable viral load after 6 days"}